Physician profile

Amara Abid

Podiatrist · Brooklyn, NY

NPI 1922505445

$473.78

in general payments reported to CMS, 2019-2025

5 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$196.43

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Integra Lifesciences Corporation $221.36 2022-2023 Integra, Integra Dermal Regeneration Template, Primatrix
Smith+Nephew, INC. $170.50 2022-2024 Stravix
Stryker Corporation $37.50 2022
Bioventus LLC $28.39 2024 Exogen Ultrasound Bone Healing System
Tactile Systems Technology INC $16.03 2023 Flexitouch Plus, Entre Plus

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Amara Abid

$473.78

in general payments reported 2019-2025

Years
2022-2024
Top company
Integra Lifesciences Corporation

https://glasscript.com/doctor/11260748/amara-abid

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.